{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:34:57Z","timestamp":1791171297159,"version":"4.1.0"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Helicobacter pylori infection results in chronic gastritis, which may progress to gastric cancer. In this study, we investigated the efficacy of H. pylori eradication in preventing the progression of gastritis to gastric cancer in H. pylori\u2013infected transgenic INS-GAS mice. H. pylori infection induced severe dysplasia and gastric cancer classified as high-grade and low-grade gastrointestinal intraepithelial neoplasia (GIN) in INS-GAS mice at 28 weeks postinfection (WPI). H. pylori eradication therapy using omeprazole, metronidazole, and clarithromycin was administered p.o. at 8, 12, or 22 WPI. Compared with untreated infected mice, H. pylori eradication at 8, 12, and 22 WPI significantly reduced the severity of dysplasia (P &amp;lt; 0.01). Moreover, H. pylori eradication at 8 WPI completely prevented the development of GIN (P &amp;lt; 0.001). Although not as effective as early antimicrobial treatment, prevention of progression to high-grade GIN was achieved by H. pylori eradication at 12 and 22 WPI (P &amp;lt; 0.05). Consistent with reduced gastric pathology, H. pylori eradication at all time points significantly down-regulated gastric Interferon-\u03b3, tumor necrosis factor-\u03b1, inducible nitric oxide synthase, and Reg 1 mRNA levels (P &amp;lt; 0.05) and reduced epithelial proliferation in the corpus (P &amp;lt; 0.01) compared with untreated infected mice. We concluded that H. pylori eradication prevented gastric cancer to the greatest extent when antibiotics are given at an early point of infection, but that eradication therapy given at a later time point delayed the development of severe dysplastic lesions. [Cancer Res 2008;68(9):3540\u20138]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-6786","type":"journal-article","created":{"date-parts":[[2008,4,26]],"date-time":"2008-04-26T00:58:56Z","timestamp":1209171536000},"page":"3540-3548","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["<i>Helicobacter pylori<\/i> Eradication Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice"],"prefix":"10.1158","volume":"68","author":[{"given":"Chung-Wei","family":"Lee","sequence":"first","affiliation":[{"name":"1Division of Comparative Medicine and"},{"name":"2Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Rickman","sequence":"additional","affiliation":[{"name":"1Division of Comparative Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlin B.","family":"Rogers","sequence":"additional","affiliation":[{"name":"1Division of Comparative Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongming","family":"Ge","sequence":"additional","affiliation":[{"name":"1Division of Comparative Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Wang","sequence":"additional","affiliation":[{"name":"3Division of Digestive and Liver Disease, Department of Medicine, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Fox","sequence":"additional","affiliation":[{"name":"1Division of Comparative Medicine and"},{"name":"2Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"2022061700423472500_B1","doi-asserted-by":"crossref","unstructured":"Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet\u20081984; 1: 1311\u20135.","DOI":"10.1016\/S0140-6736(84)91816-6"},{"key":"2022061700423472500_B2","unstructured":"International Agency for Research on Cancer. Schistosomes, liver flukes, and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum\u20081994; 61: 1\u2013241."},{"key":"2022061700423472500_B3","doi-asserted-by":"crossref","unstructured":"Fox JG, Wang TC. Helicobacter pylori\u2014not a good bug after all! N Engl J Med\u20082001; 345: 829\u201332.","DOI":"10.1056\/NEJM200109133451111"},{"key":"2022061700423472500_B4","unstructured":"Correa P. A human model of gastric carcinogenesis. Cancer Res\u20081988; 48: 3554\u201360."},{"key":"2022061700423472500_B5","doi-asserted-by":"crossref","unstructured":"Ley C, Mohar A, Guarner J, et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev\u20082004; 13: 4\u201310.","DOI":"10.1158\/1055-9965.EPI-03-0124"},{"key":"2022061700423472500_B6","doi-asserted-by":"crossref","unstructured":"You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst\u20082006; 98: 974\u201383.","DOI":"10.1093\/jnci\/djj264"},{"key":"2022061700423472500_B7","doi-asserted-by":"crossref","unstructured":"Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther\u20082002; 16: 1449\u201356.","DOI":"10.1046\/j.1365-2036.2002.01311.x"},{"key":"2022061700423472500_B8","doi-asserted-by":"crossref","unstructured":"Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst\u20082000; 92: 1881\u20138.","DOI":"10.1093\/jnci\/92.23.1881"},{"key":"2022061700423472500_B9","doi-asserted-by":"crossref","unstructured":"Mera R, Fontham ET, Bravo LE, et al. Long-term follow-up of patients treated for Helicobacter pylori infection. Gut\u20082005; 54: 1536\u201340.","DOI":"10.1136\/gut.2005.072009"},{"key":"2022061700423472500_B10","doi-asserted-by":"crossref","unstructured":"Nyren O, McLaughlin JK, Gridley G, et al. Cancer risk after hip replacement with metal implants: a population-based cohort study in Sweden. J Natl Cancer Inst\u20081995; 87: 28\u201333.","DOI":"10.1093\/jnci\/87.1.28"},{"key":"2022061700423472500_B11","unstructured":"Akre K, Signorello LB, Engstrand L, et al. Risk for gastric cancer after antibiotic prophylaxis in patients undergoing hip replacement. Cancer Res\u20082000; 60: 6376\u201380."},{"key":"2022061700423472500_B12","doi-asserted-by":"crossref","unstructured":"Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA\u20082004; 291: 187\u201394.","DOI":"10.1001\/jama.291.2.187"},{"key":"2022061700423472500_B13","doi-asserted-by":"crossref","unstructured":"Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut\u20082004; 53: 1244\u20139.","DOI":"10.1136\/gut.2003.034629"},{"key":"2022061700423472500_B14","doi-asserted-by":"crossref","unstructured":"Cao X, Tsukamoto T, Nozaki K, et al. Eradication of Helicobacter pylori induces apoptosis and inhibits proliferation of heterotopic proliferative glands in infected Mongolian gerbils. Cancer Sci\u20082004; 95: 872\u20137.","DOI":"10.1111\/j.1349-7006.2004.tb02196.x"},{"key":"2022061700423472500_B15","doi-asserted-by":"crossref","unstructured":"Cai X, Carlson J, Stoicov C, Li H, Wang TC, Houghton J. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL\/6 mice. Gastroenterology\u20082005; 128: 1937\u201352.","DOI":"10.1053\/j.gastro.2005.02.066"},{"key":"2022061700423472500_B16","doi-asserted-by":"crossref","unstructured":"Fox JG, Wang TC, Rogers AB, et al. Host and microbial constituents influence Helicobacter pylori-induced cancer in a murine model of hypergastrinemia. Gastroenterology\u20082003; 124: 1879\u201390.","DOI":"10.1016\/S0016-5085(03)00406-2"},{"key":"2022061700423472500_B17","doi-asserted-by":"crossref","unstructured":"Konda Y, Kamimura H, Yokota H, Hayashi N, Sugano K, Takeuchi T. Gastrin stimulates the growth of gastric pit with less-differentiated features. Am J Physiol\u20081999; 277: G773\u201384.","DOI":"10.1152\/ajpgi.1999.277.4.G773"},{"key":"2022061700423472500_B18","doi-asserted-by":"crossref","unstructured":"Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology\u20082000; 118: 36\u201347.","DOI":"10.1016\/S0016-5085(00)70412-4"},{"key":"2022061700423472500_B19","unstructured":"Fox JG, Rogers AB, Ihrig M, et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res\u20082003; 63: 942\u201350."},{"key":"2022061700423472500_B20","doi-asserted-by":"crossref","unstructured":"Wang TC, Koh TJ, Varro A, et al. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest\u20081996; 98: 1918\u201329.","DOI":"10.1172\/JCI118993"},{"key":"2022061700423472500_B21","doi-asserted-by":"crossref","unstructured":"Ohtani M, Garcia A, Rogers AB, et al. Protective role of 17\u03b2-estradiol against the development of Helicobacter pylori-induced gastric cancer in INS-GAS mice. Carcinogenesis\u20082007; 28: 2597\u2013604.","DOI":"10.1093\/carcin\/bgm150"},{"key":"2022061700423472500_B22","doi-asserted-by":"crossref","unstructured":"Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology\u20081997; 112: 1386\u201397.","DOI":"10.1016\/S0016-5085(97)70155-0"},{"key":"2022061700423472500_B23","doi-asserted-by":"crossref","unstructured":"Lee CW, Rao VP, Rogers AB, et al. Wild-type and interleukin-10-deficient regulatory T cells reduce effector T-cell-mediated gastroduodenitis in Rag2\u2212\/\u2212 mice, but only wild-type regulatory T cells suppress Helicobacter pylori gastritis. Infect Immun\u20082007; 75: 2699\u2013707.","DOI":"10.1128\/IAI.01788-06"},{"key":"2022061700423472500_B24","doi-asserted-by":"crossref","unstructured":"van Zanten SJ, Kolesnikow T, Leung V, O'Rourke JL, Lee A. Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. Antimicrob Agents Chemother\u20082003; 47: 2249\u201355.","DOI":"10.1128\/AAC.47.7.2249-2255.2003"},{"key":"2022061700423472500_B25","doi-asserted-by":"crossref","unstructured":"Rogers AB, Taylor NS, Whary MT, Stefanich ED, Wang TC, Fox JG. Helicobacter pylori but not high salt induces gastric intraepithelial neoplasia in B6129 mice. Cancer Res\u20082005; 65: 10709\u201315.","DOI":"10.1158\/0008-5472.CAN-05-1846"},{"key":"2022061700423472500_B26","doi-asserted-by":"crossref","unstructured":"Boivin GP, Washington K, Yang K, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology\u20082003; 124: 762\u201377.","DOI":"10.1053\/gast.2003.50094"},{"key":"2022061700423472500_B27","doi-asserted-by":"crossref","unstructured":"Maurer KJ, Rogers AB, Ge Z, Wiese AJ, Carey MC, Fox JG. Helicobacter pylori and cholesterol gallstone formation in C57L\/J mice: a prospective study. Am J Physiol Gastrointest Liver Physiol\u20082006; 290: G175\u201382.","DOI":"10.1152\/ajpgi.00272.2005"},{"key":"2022061700423472500_B28","doi-asserted-by":"crossref","unstructured":"Ihrig M, Whary MT, Dangler CA, Fox JG. Gastric Helicobacter infection induces a Th2 phenotype but does not elevate serum cholesterol in mice lacking inducible nitric oxide synthase. Infect Immun\u20082005; 73: 1664\u201370.","DOI":"10.1128\/IAI.73.3.1664-1670.2005"},{"key":"2022061700423472500_B29","doi-asserted-by":"crossref","unstructured":"Fukui H, Kinoshita Y, Maekawa T, et al. Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats. Gastroenterology\u20081998; 115: 1483\u201393.","DOI":"10.1016\/S0016-5085(98)70027-7"},{"key":"2022061700423472500_B30","doi-asserted-by":"crossref","unstructured":"Takaishi S, Cui G, Frederick DM, et al. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology\u20082005; 128: 1965\u201383.","DOI":"10.1053\/j.gastro.2005.03.027"},{"key":"2022061700423472500_B31","doi-asserted-by":"crossref","unstructured":"Li Q, Karam SM, Gordon JI. Diphtheria toxin-mediated ablation of parietal cells in the stomach of transgenic mice. J Biol Chem\u20081996; 271: 3671\u20136.","DOI":"10.1074\/jbc.271.7.3671"},{"key":"2022061700423472500_B32","doi-asserted-by":"crossref","unstructured":"Kang W, Rathinavelu S, Samuelson LC, Merchant JL. Interferon \u03b3 induction of gastric mucous neck cell hypertrophy. Lab Invest\u20082005; 85: 702\u201315.","DOI":"10.1038\/labinvest.3700260"},{"key":"2022061700423472500_B33","doi-asserted-by":"crossref","unstructured":"Fox JG, Rogers AB, Whary MT, et al. Accelerated progression of gastritis to dysplasia in the pyloric antrum of TFF2\/C57BL6 \u00d7 Sv129 Helicobacter pylori-infected mice. Am J Pathol\u20082007; 171: 1520\u20138.","DOI":"10.2353\/ajpath.2007.070249"},{"key":"2022061700423472500_B34","doi-asserted-by":"crossref","unstructured":"Biasco G, Paganelli GM, Miglioli M, Barbara L. Cell proliferation biomarkers in the gastrointestinal tract. J Cell Biochem\u20081992; 16G: 73\u20138.","DOI":"10.1002\/jcb.240501114"},{"key":"2022061700423472500_B35","unstructured":"Biasco G, Paganelli GM, Santucci R, Miglioli M, Barbara L. Cell proliferation kinetics as a marker of gastric cancer risk. Ital J Gastroenterol\u20081991; 23: 24\u20138."},{"key":"2022061700423472500_B36","doi-asserted-by":"crossref","unstructured":"Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A\u20082006; 103: 732\u20137.","DOI":"10.1073\/pnas.0506655103"},{"key":"2022061700423472500_B37","doi-asserted-by":"crossref","unstructured":"Sarma-Rupavtarm RB, Ge Z, Schauer DB, Fox JG, Polz MF. Spatial distribution and stability of the eight microbial species of the altered Schaedler flora in the mouse gastrointestinal tract. Appl Environ Microbiol\u20082004; 70: 2791\u2013800.","DOI":"10.1128\/AEM.70.5.2791-2800.2004"},{"key":"2022061700423472500_B38","doi-asserted-by":"crossref","unstructured":"Zavros Y, Rieder G, Ferguson A, Merchant JL. Gastritis and hypergastrinemia due to Acinetobacter lwoffii in mice. Infect Immun\u20082002; 70: 2630\u20139.","DOI":"10.1128\/IAI.70.5.2630-2639.2002"},{"key":"2022061700423472500_B39","doi-asserted-by":"crossref","unstructured":"Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest\u20082007; 117: 60\u20139.","DOI":"10.1172\/JCI30111"},{"key":"2022061700423472500_B40","doi-asserted-by":"crossref","unstructured":"Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother\u20081999; 44: 629\u201340.","DOI":"10.1093\/jac\/44.5.629"},{"key":"2022061700423472500_B41","doi-asserted-by":"crossref","unstructured":"Sung J, Lin S, Ching J, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology\u20082000; 119: 7\u201314.","DOI":"10.1053\/gast.2000.8550"},{"key":"2022061700423472500_B42","unstructured":"International Agency for Research on Cancer. Cancer incidence in five continents. In: Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Vol. 7. Lyon: IARC Sci Publ; 1997."},{"key":"2022061700423472500_B43","doi-asserted-by":"crossref","unstructured":"Mera R, Fontham ET, Bravo LE, et al. Re: Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst\u20082006; 98: 1426.","DOI":"10.1093\/jnci\/djj388"},{"key":"2022061700423472500_B44","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut\u20082007; 56: 772\u201381.","DOI":"10.1136\/gut.2006.101634"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/9\/3540\/2602702\/3540.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/9\/3540\/2602702\/3540.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T06:40:40Z","timestamp":1655448040000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/9\/3540\/543314\/Helicobacter-pylori-Eradication-Prevents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,1]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2008,5,1]]},"published-print":{"date-parts":[[2008,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-6786","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,1]]}}}